4.7 Review

Targeted nanotechnology for cancer imaging

Journal

ADVANCED DRUG DELIVERY REVIEWS
Volume 76, Issue -, Pages 79-97

Publisher

ELSEVIER
DOI: 10.1016/j.addr.2014.08.002

Keywords

Targeted nanoparticles; Cancer imaging; MRI; CT; Ultrasound; PET; SPECT; Optical imaging

Funding

  1. National Cancer Institute [R01CA177716]
  2. Clinical and Translational Science Collaborative of Cleveland from the National Center for Advancing Translational Sciences component of the National Institutes of Health [UL1TR000439]
  3. Ohio Cancer Research Associates
  4. NIH Interdisciplinary Biomedical Imaging Training Program [T32EB007509]
  5. National Cancer Institute Training Program in Cancer Pharmacology [R25CA148052]

Ask authors/readers for more resources

Targeted nanoparticle imaging agents provide many benefits and new opportunities to facilitate accurate diagnosis of cancer and significantly impact patient outcome. Due to the highly engineerable nature of nanotechnology, targeted nanoparticles exhibit significant advantages including increased contrast sensitivity, binding avidity and targeting specificity. Considering the various nanoparticle designs and their adjustable ability to target a specific site and generate detectable signals, nanoparticles can be optimally designed in terms of biophysical interactions (i.e., intravascular and interstitial transport) and biochemical interactions (i.e., targeting avidity towards cancer-related biomarkers) for site-specific detection of very distinct microenvironments. This review seeks to illustrate that the design of a nanoparticle dictates its in vivo journey and targeting of hard-to-reach cancer sites, facilitating early and accurate diagnosis and interrogation of the most aggressive forms of cancer. We will report various targeted nanoparticles for cancer imaging using X-ray computed tomography, ultrasound, magnetic resonance imaging, nuclear imaging and optical imaging. Finally, to realize the full potential of targeted nanotechnology for cancer imaging, we will describe the challenges and opportunities for the clinical translation and widespread adaptation of targeted nanoparticles imaging agents. (C) 2014 Elsevier B.V. All rights reserved

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available